BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 9522035)

  • 1. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
    Kimura K; Tominaga K; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
    Nakano S; Kihara Y; Otsuki M
    Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
    Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
    Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models.
    Satake K; Kimura K; Saito T
    Digestion; 1999; 60 Suppl 1():64-8. PubMed ID: 10026435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholecystokinin antagonistic activities of loxiglumide.
    Wakatsuki K; Saito T; Saeki M; Ninomiya K; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1997 Oct; 47(10):1130-3. PubMed ID: 9368707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
    Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of gabexate mesilate on serum inflammatory cytokines in rats with acute necrotizing pancreatitis.
    Chen CC; Wang SS; Tsay SH; Lee FY; Lu RH; Chang FY; Lee SD
    Cytokine; 2006 Jan; 33(2):95-9. PubMed ID: 16473521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
    Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats.
    Otsuki M; Tani S; Okabayshi Y; Nakamura T; Fujii M; Fujisawa T; Baba S; Itoh H
    Pancreas; 1989; 4(2):237-43. PubMed ID: 2474165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs.
    Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Edano K; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1998 Jan; 48(1):55-7. PubMed ID: 9522033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
    Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
    J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats.
    Kanemitsu D; Sakagami J; Motoyoshi T; Nakajima T; Kataoka K
    Pancreas; 2006 Mar; 32(2):190-6. PubMed ID: 16552340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of gabexate mesilate on pancreatic and hepatic microcirculation in acute experimental pancreatitis in rats.
    Chen HM; Hwang TL; Chen MF
    J Surg Res; 1996 Dec; 66(2):147-53. PubMed ID: 9024827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loxiglumide protects against experimental pancreatitis.
    Setnikar I; Bani M; Cereda R; Chisté R; Makovec F; Pacini MA; Revel L
    Arzneimittelforschung; 1987 Oct; 37(10):1172-4. PubMed ID: 3435590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a cholecystokinin receptor antagonist lorglumid on the proteinase-antiproteinase balance in taurocholate acute experimental pancreatitis (AEP) in rats.
    Kosidło S; Rydzewska G; Gabryelewicz A
    Mater Med Pol; 1992; 24(4):223-6. PubMed ID: 1308047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
    Otsuki M; Nakano S; Tachibana I
    Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of adenosine receptors on the development of caerulein-induced acute pancreatitis.
    Szczerbiński M; Celiński K; Słomka M; Kasztelan-Szczerbińska B; Cichoz-Lach H
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):245-56. PubMed ID: 12898930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
    Tani S; Itoh H; Koide M; Okabayashi Y; Otsuki M
    Pancreas; 1993 Jan; 8(1):109-15. PubMed ID: 7678322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.